What is the standard Enclomiphene dosing protocol?

See the fact-checked Verified Dosing shown at the top of this page (verified against the FDA label / published trials); always confirm with a licensed provider.

How do you take Enclomiphene?

Enclomiphene is an oral compound supplied as capsules. No reconstitution is required. Swallow the capsule with water at the same time each day.

What are the storage requirements for Enclomiphene?

Store capsules at room temperature in a cool, dry place. Keep tightly sealed, away from moisture and direct light. Use within 90 days of opening.

Enclomiphene — Research Literature Summary

✓ Verified dosing (fact-checked against FDA labels / published trials): Oral, once-daily. Studied doses: 6.25, 12.5, and 25 mg per day (capsule, swallowed). Typical effective range 12.5-25 mg once daily; 25 mg/day is the higher-efficacy dose for raising total testosterone in secondary hypogonadism. Continuous daily use, NOT a weekly total or intermittent "protocol-day" regimen. No FDA-approved label exists; figures are from… This supersedes any conflicting figures shown elsewhere on this page; confirm with a licensed provider.

Class: Investigational SERM • Page type: research-literature reference • Updated 2026-04-23

Regulatory notice — research reference only

Enclomiphene citrate (Androxal) is an investigational selective estrogen receptor modulator (SERM). Its U.S. Phase III development program (by Repros Therapeutics) was halted; enclomiphene is NOT FDA-approved for any indication. This page summarizes the published clinical research literature only. Not for human use.

Published research summary

Enclomiphene is the trans-isomer of clomiphene citrate. In Phase II and Phase III studies, oral enclomiphene raised serum testosterone in men with secondary hypogonadism while preserving sperm concentrations - in contrast to exogenous testosterone, which suppresses spermatogenesis.
Repros Therapeutics' Phase III submission (NDA 204321) received a Complete Response Letter from the FDA in 2015 citing concerns about the bioequivalence endpoint. Development for that indication did not resume.
Published clinical trials studied 12.5 mg/day and 25 mg/day oral doses for 3-6 months in men with secondary hypogonadism.
Common adverse effects reported included headache, nausea, hot flashes, mood changes, and visual disturbances (a known SERM-class effect). Long-term cardiovascular and vision safety beyond trial durations is not established in peer-reviewed literature.

Why this page does not publish a consumer “cycle” schedule

Enclomiphene is not FDA-approved. 'Cycle,' 'PCT,' or 'testosterone enhancement' framing is consumer-market language, not a reflection of the peer-reviewed research record.

Peer-reviewed citations

Wiehle RD, et al. J Androl 2014;35(2):244-251 (Phase II).
Kaminetsky J, et al. BJU Int 2013;112(8):1188-1200.
FDA Complete Response Letter for Androxal (enclomiphene), Repros Therapeutics press release, 2015.

Consulting a healthcare provider: This page is a reference for published research. If you are considering any health decision, consult a licensed healthcare provider. Path to Peptides does not provide medical advice.

⚠ Before any use: human safety data is limited or absent for many of these compounds. Consult a licensed healthcare provider first — especially if you are pregnant or nursing, have a medical condition, or take other medications.